tradingkey.logo

Charles River Laboratories International Inc

CRL
查看詳細走勢圖
189.210USD
+5.620+3.06%
收盤 02/06, 16:00美東報價延遲15分鐘
9.31B總市值
虧損本益比TTM

Charles River Laboratories International Inc

189.210
+5.620+3.06%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.06%

5天

-10.11%

1月

-12.71%

6月

+26.33%

今年開始到現在

-5.15%

1年

+15.52%

查看詳細走勢圖

操作建議

Charles River Laboratories International Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名14/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為217.09。中期看,股價處於上升通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Charles River Laboratories International Inc評分

相關信息

行業排名
14 / 392
全市場排名
100 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Charles River Laboratories International Inc亮點

亮點風險
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
行業龍頭
公司營業收入處於行業前列,最新年度總收入4.05B美元
估值低估
公司最新PE估值-123.68,處於3年歷史低位
機構加倉
最新機構持股52.25M股,環比增加0.05%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉1.10M股

分析師目標

基於 19 分析師
買入
評級
217.091
目標均價
+7.67%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Charles River Laboratories International Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Charles River Laboratories International Inc簡介

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
公司代碼CRL
公司Charles River Laboratories International Inc
CEOFoster (James C)
網址https://www.criver.com/
KeyAI